Why the study?
Does recombinant interleukin-2 therapy cause myocardial toxic effects in patients with metastatic solid tumors?
Does recombinant interleukin-2 therapy cause myocardial toxic effects in patients with metastatic solid tumors?
Answers are grounded in this paper and cite their sources.
Recombinant interleukin-2 therapy in patients with metastatic solid tumors is associated with severe cardiovascular toxicity, including myocardial infarction and reduced cardiac contractility.
Arterial and pulmonary artery catheters were used to monitor the cardiopulmonary effects of recombinant interleukin-2 (rIL-2) given iv at a dose of 100,000 U/kg every 8 hours on days 1-5 to 10 patients with metastatic solid tumors. As anticipated, a severe capillary leak syndrome developed in all patients. Myocardial infarction (MI) occurred unexpectedly in three patients, as evidenced by a focal injury pattern on ECG and elevations of creatinine phosphokinase myocardial band fractions. All patients receiving rIL-2 exhibited major reductions in their left ventricular stroke work index (47 +/- 11 g.m/m2 to 29 +/- g.m/m2), an index of cardiac contractility. It remains uncertain whether the MIs were a byproduct of the capillary leak syndrome in patients with underlying coronary artery disease or whether rIL-2 directly or indirectly damages cardiac muscle.
No takes yet. Share an insight, caveat, or question.
Nora et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: